Cellectis S.A.

CLLS

$3.32

+2.15%

N/A+$0.07

Healthcare

Biotechnology

NASDAQ

Active Trading

Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited ...

Financial Highlights of CLLS

Profitability trend

Latest / TTM · 6 periods

Gross Margin

74.7%

Net Margin

-115.4%

P/E Ratio

-5.24x

n/a

Debt / Equity

2.06

n/a

Current Ratio

1.37

Dividend Yield

0.0%

Understanding

TTM —

High debt to equity

Interest coverage is weak

Financial highlights

Latest / TTM · 6 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

74.7%

Net Margin

-115.4%

P/E Ratio

-5.24x

Debt / Equity

2.06

Profitability

Profitability table

Metric	2021	2022	2023	2024	2025	2026
Gross MarginGross profit as a percentage of revenue.	93.9%	55.7%	-882.6%	77.9%	86.6%	—
Operating MarginOperating income as a percentage of revenue.	-341.0%	-467.7%	-12887.7%	-143.5%	-45.3%	—
Net MarginNet income as a percentage of revenue.	-376.3%	-553.6%	-13385.3%	-88.6%	-92.7%	—
EBITDA MarginEBITDA divided by revenue.	-258.4%	-398.4%	-12269.8%	-22.8%	-54.6%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	-318.8%	-514.3%	-15425.7%	-88.6%	-93.2%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2021	2022	2023	2024	2025	2026
Current RatioCurrent assets divided by current liabilities.	4.57	2.28	1.50	1.73	1.62	—
Quick RatioLiquid assets divided by current liabilities.	4.57	2.28	1.50	1.73	1.62	—
Cash RatioCash and equivalents divided by current liabilities.	3.76	1.43	0.88	0.86	0.44	—
Debt / AssetsDebt as a share of total assets.	26.4%	29.0%	25.4%	23.8%	36.9%	—
Debt / EquityDebt compared with shareholder equity.	0.46	0.64	1.00	0.70	1.58	—

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	2026
Receivables TurnoverHow often receivables are collected in a year.	0.98x	1.09x	0.03x	1.80x	2.88x	—
Inventory TurnoverHow often inventory is sold in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Payables TurnoverHow often payables are paid in a year.	0.08x	0.40x	0.39x	0.49x	0.57x	—
Asset TurnoverRevenue generated per dollar of assets.	0.08x	0.07x	0.00x	0.11x	0.22x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	0.14x	0.15x	0.01x	0.42x	0.69x	—

Valuation ratios

Valuation ratios table

Metric	2021	2022	2023	2024	2025	2026
P/E RatioPrice paid for each dollar of earnings.	-3.02x	-0.90x	-1.74x	-4.39x	-7.12x	—
P/B RatioPrice paid for each dollar of book value.	1.56x	0.81x	2.07x	1.24x	6.39x	—
P/S RatioPrice paid for each dollar of sales.	11.36x	4.99x	232.58x	3.93x	6.65x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	-2.80x	-1.06x	-6.80x	8.35x	-11.42x	—
Dividend YieldAnnual dividend divided by current share price.	0.0%	0.0%	0.0%	0.0%	0.0%	—

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer